Dr. Jyotsna Priyam
IIT Mandi · ICGEB · AI-Driven Digital Health · Founder, Biomedical AI Platforms
Which Drugs Open Up Next: A Practical Guide to Patent Expiries, Generic Launches and API Sourcing
About $236 billion in drug sales loses patent protection by 2030. How I work out which molecules open up, in which countries, and who can supply the API — plus the tool I'm building to do it at scale.
Insilico Medicine's AI-Designed Drug Clears Phase 2a for Idiopathic Pulmonary Fibrosis
Both the drug and its target were designed by AI. It just cleared phase 2a for a serious lung disease.
AI Drug Discovery Is Shifting From Reading Genetic Code to Understanding What It Does
Knowing every word in a dictionary doesn't mean you understand a language. Most AI models in biology have the same problem.
The Secret Ingredient in Merck & Moderna's Cancer Vaccine Is an Algorithm
A cancer vaccine whose genetic sequence was written by an algorithm, not a chemist. It just cleared a late-stage trial.
When AI Starts Reading the Genome: The Biotech Signals to Watch
Three stories from the last few weeks convinced me AI has stopped being a tool bolted onto biotech — it's becoming the infrastructure underneath it.